Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1983-8-17
|
pubmed:abstractText |
AT-2266, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3 -carboxylic acid, is a new pyridonecarboxylic acid derivative with broad and potent antibacterial activity. It inhibited some gram-positive bacteria, such as staphylococci and Bacillus subtilis, and most gram-negative bacteria, including Serratia marcescens, Pseudomonas aeruginosa, Haemophilus influenzae, and Campylobacter jejuni, at concentrations of 0.1 to 0.78 microgram/ml, and most gram-positive bacteria, glucose-nonfermenters, and Mycoplasma pneumoniae at concentrations of 1.56 to 12.5 micrograms/ml. Most of the clinical isolates tested were as susceptible to AT-2266 as were laboratory strains. The antibacterial potency of AT-2266 was higher than those of pipemidic acid and nalidixic acid and similar to that of norfloxacin. AT-2266 was not cross-resistant with antibiotics and inhibited most highly nalidixic acid-resistant bacteria at concentrations of 1.56 to 3.13 micrograms/ml. Its activity was barely affected by the addition of horse serum or sodium cholate but weakened by lowering the medium pH or increasing the inoculum size. AT-2266 was bactericidal at concentrations near its minimal inhibitory concentrations. Frequencies of mutants resistant to 10 micrograms of AT-2266 per ml were lower than 4.0 x 10(-9).
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/6575721-1147584,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6575721-14056431,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6575721-4791302,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6575721-6211139,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6575721-6213200,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6575721-6446258,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6575721-7452690,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6575721-810076
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0066-4804
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
641-8
|
pubmed:dateRevised |
2009-11-18
|
pubmed:meshHeading |
pubmed-meshheading:6575721-Anti-Bacterial Agents,
pubmed-meshheading:6575721-Bacteria,
pubmed-meshheading:6575721-Bacterial Infections,
pubmed-meshheading:6575721-Cholic Acid,
pubmed-meshheading:6575721-Cholic Acids,
pubmed-meshheading:6575721-Drug Resistance, Microbial,
pubmed-meshheading:6575721-Enoxacin,
pubmed-meshheading:6575721-Humans,
pubmed-meshheading:6575721-Hydrogen-Ion Concentration,
pubmed-meshheading:6575721-Microbial Sensitivity Tests,
pubmed-meshheading:6575721-Mutation,
pubmed-meshheading:6575721-Naphthyridines
|
pubmed:year |
1983
|
pubmed:articleTitle |
In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.
|
pubmed:publicationType |
Journal Article
|